Nano-Oncology: Clinical Application for Cancer Therapy and Future Perspectives

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">  </td><td align="center">Half-life time</td><td align="center">AUC<br/> (Area Under Curve)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Free doxorubicin</td><td align="center">0.2 h</td><td align="center">4 <i>μ</i>gh/mL</td></tr><tr><td align="left">Myocet</td><td align="center">2.5 h</td><td align="center">45 <i>μ</i>gh/mL</td></tr><tr><td align="left">Caelyx/Doxil</td><td align="center">55 h</td><td align="center">900 <i>μ</i>gh/mL</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Values for half-life and AUC for two liposomal formulations and free doxorubicin. 

Journal of Nanomaterials

tab3

Table 3

Table 3: Nano-Oncology: Clinical Application for Cancer Therapy and Future Perspectives 